CME in Minutes: Education in Oncology & Hematology – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Podcast CME in Minutes: Education in Oncology & Hematology

CME in Minutes: Education in Oncology & Hematology

Answers in CME

Science
Health & Fitness

Frequency: 1 episode/7d. Total Eps: 133

Hosting podcast Unknown
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Site
RSS
Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

  • 🇺🇸 USA - lifeSciences

    16/06/2026
    #76

  • 🇺🇸 USA - lifeSciences

    14/06/2026
    #98

  • 🇬🇧 Great Britain - lifeSciences

    13/06/2026
    #87

  • 🇺🇸 USA - lifeSciences

    13/06/2026
    #70

  • 🇬🇧 Great Britain - lifeSciences

    12/06/2026
    #77

  • 🇺🇸 USA - lifeSciences

    12/06/2026
    #74

  • 🇬🇧 Great Britain - lifeSciences

    11/06/2026
    #56

  • 🇬🇧 Great Britain - lifeSciences

    10/06/2026
    #48

  • 🇬🇧 Great Britain - lifeSciences

    09/06/2026
    #32

  • 🇺🇸 USA - lifeSciences

    05/06/2026
    #71

Spotify

    No recent rankings available

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all
RSS feed quality
To improve

Score global : 53%

Publication history

Monthly episode publishing history over the past years.

Episodes published by month in

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

lundi 9 septembre 2024 • Duration 12:35

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

lundi 9 septembre 2024 • Duration 12:49

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

Ghassan Abou-Alfa, MD, MBA - Getting On the Right Tract: Patient-Centered Strategies to Diagnose Biliary Tract Cancers

jeudi 4 juillet 2024 • Duration 11:47

Please visit answersincme.com/CKZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses patient-centered approaches to the diagnosis and treatment of biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the importance of achieving an accurate diagnosis of biliary tract cancer (BTC); Outline strategies for reaching a diagnosis of BTC, including cholangiocarcinoma; and Describe patient-centered approaches to enhance outcomes for patients undergoing a diagnostic work-up for BTC.

Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options

jeudi 4 juillet 2024 • Duration 18:53

Please visit answersincme.com/UWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses chemoimmunotherapy treatment of advanced squamous cell non-small cell lung cancer without molecular alterations. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of approved chemoimmunotherapy combinations for treatment of patients with advanced squamous cell non-small cell lung cancer (NSCLC) without molecular alterations; Review clinical factors for individualizing first-line treatment of patients with advanced squamous cell NSCLC; and Identify real-world factors that impact treatment selection for patients with advanced squamous cell NSCLC. This activity is intended for US healthcare professionals only.

Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens

mardi 25 juin 2024 • Duration 14:57

Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.

Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence

mardi 25 juin 2024 • Duration 14:24

Please visit answersincme.com/VMK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of novel therapies for patients with transfusion-dependent beta thalassemia. Upon completion of this activity, participants should be better able to: Describe the limitations of ongoing transfusions for patients with transfusion-dependent beta thalassemia (TDT); Review the evidence on novel therapies for TDT; and Outline shared decision-making strategies for the potential use of novel therapies for patients with TDT.

Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy

mardi 18 juin 2024 • Duration 13:22

Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.

Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer

mardi 28 mai 2024 • Duration 15:26

Please visit answersincme.com/TSH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of metastatic colorectal cancer (mCRC) discuss sequencing strategies to enhance patient quality of life during later-line treatment. Upon completion of this activity, participants should be better able to: Describe the latest data for later-line treatment sequencing for patients with mCRC; Outline evidence-based strategies to optimally sequence later-line treatment options for mCRC; and Explain tactics for addressing quality of life and survivorship with patients in later lines of treatment for mCRC.

Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations

mardi 30 avril 2024 • Duration 15:23

Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

vendredi 5 avril 2024 • Duration 13:42

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.

Related Shows Based on Content Similarities

Discover shows related to CME in Minutes: Education in Oncology & Hematology, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
There is no related content for this show.
© My Podcast Data
About usPrivacy Policy